Scotia Capital Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 166,880 shares of the company’s stock after buying an additional 7,000 shares during the period. Scotia Capital Inc.’s holdings in Novo Nordisk A/S were worth $7,157,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of NVO. Neuberger Berman Group LLC boosted its stake in shares of Novo Nordisk A/S by 23.6% during the 1st quarter. Neuberger Berman Group LLC now owns 44,327 shares of the company’s stock worth $1,520,000 after buying an additional 8,477 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $17,406,000. Tekla Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $2,845,000. Mackenzie Financial Corp boosted its stake in shares of Novo Nordisk A/S by 83.5% during the 1st quarter. Mackenzie Financial Corp now owns 47,435 shares of the company’s stock worth $1,626,000 after buying an additional 21,589 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Novo Nordisk A/S by 3,609.0% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after buying an additional 3,609 shares during the last quarter. Institutional investors own 6.01% of the company’s stock.
NVO has been the subject of a number of recent research reports. BidaskClub upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, June 15th. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Finally, BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $55.00.
WARNING: “Scotia Capital Inc. Acquires 7,000 Shares of Novo Nordisk A/S (NVO)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/10/11/scotia-capital-inc-acquires-7000-shares-of-novo-nordisk-as-nvo.html.
Shares of Novo Nordisk A/S (NVO) traded up 0.74% during midday trading on Wednesday, hitting $49.19. 1,030,984 shares of the stock were exchanged. The stock has a market capitalization of $96.54 billion, a price-to-earnings ratio of 19.79 and a beta of 0.61. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $49.50. The firm’s 50 day moving average is $48.04 and its 200-day moving average is $42.78.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.